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Introduction 
The renin-angiotensin system has been thought of as 
an endocrine system whose effects are mediated 
through the peptide hormone angiotensin II in the 
circulation. Angiotensin II is the final active product of 
the biological cascade which begins with hypotension, 
hypovolaemia, haemorrhage, or severe heart failure. 
These events result in release of renin from the kidney. 
Circulating renin cleaves the decapeptide angiotensin 
I from angiotensinogen. Angiotensin I is converted to 
angiotensin II by angiotensin converting enzyme 
(ACE), an event which was thought o occur primarily 
in the lung. 
Circulating angiotensin II binds to receptors in 
many organs and thus affects short-term cardiovas- 
cular homeostasis. The effects of activation of these 
receptors include vasoconstriction, release of aldoster- 
one from the adrenal secretion of vasopressin by the 
pituitary, and sodium retention by the kidney. The net 
effect is to increase circulating blood volume and raise 
blood pressure. The entire system is subject o feed- 
back inhibition and thus is inactivated when the 
conditions mentioned above are reversed. 
This view of the renin-angiotensin system prevailed 
until the past 10 years. There is now convincing 
evidence that, apart from renin production in the 
kidne~ a local or tissue renin-angiotensin system 
exists in many peripheral arteries and veins. ~'2 These 
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local renin-angiotensin systems have been shown to 
effect vascular tone and to interfere with blood 
pressure control in hypertensive patients. 3'4 They may 
also play an integral role in the control of the 
proliferative response of the vessel to intimal injury 
and hypertension. 5'6 The overall role of this tissue 
renin-angiotensin system in vascular emodelling has 
implications for the vascular surgeon. Tissue renin- 
angiotensin systems appear to be altered in vein grafts 
and to have a role in the development of intimal 
hyperplasia. 7 This review examines the renin-angio- 
tensin system in terms of historical perspectives, 
evidence for the existence of tissue renin-angiotensin 
system and the interactions between tissue renin- 
angiotensin system and the proliferative response of 
blood vessels to injury. Possible therapeutic inter- 
ventions are reviewed with particular emphasis on 
balloon angioplasty and vein grafting. 
Historical 
The role of the kidney in cardiovascular homeostasis 
was first postulated by Tigerstedt and Bergman in 
1898. sThey reported that injection of an animal with a 
kidney extract could cause a prolonged rise in arterial 
pressure and subsequently called the substance renin. 
Goldblatt et al. demonstrated that renal ischaemia was 
the primary stimulus for the release of renin and the 
cause of renovascular hypertension. 9 The "substance" 
causing renovascular hypertension was subsequently 
identified as renin. 1° In 1940 it was shown that 
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renovascular hypertension was the result of the action 
of renin on renin substrate (subsequently identified as 
angiotensinogen) resulting in the formation of angio- 
tensin I (initially termed angiotonin). 11"12 The exact 
biologic cascade became fully understood in the late 
1950's and it was shown that the major site for 
angiotensin II formation was the pulmonary circula- 
tionJ B The renal - pulmonary axis of the renin- 
angiotensin system was the focus of investigative 
activity into the renin-angiotensin system until the 
past 10 years. 
The presence of arterial wall renin in peripheral 
blood vessels was suggested in 1947 by Jimenez-Diaz 
et aI. 14 In 1966, Gould et al. first demonstrated arterial 
and venous wall renin) 5 Since the development of 
ACE inhibitors and their widespread use in hyper- 
tension and cardiac failure, there has been an explo- 
sion of interest in what has been termed local or tissue 
renin - angiotensin systems. It has been shown that all 
the components of the renin-angiotensin system, 
namely renin, angiotensinogen, ACE, angiotensin I 
and angiotensin II are present in the walls of large and 
medium sized peripheral vesselsJ 6It has been postu- 
lated that these local renin-angiotensin systems are 
involved in the control of local vessel tone, and may 
indeed be responsible for the genesis of essential 
hypertension. 5 It has been suggested by other 
workers that these systems may also be involved in 
more complex long term local cardiovascular 
homeostasis .6,17,18 
Local Renin-Angiotensin Systems 
Multiple lines of evidence support the existence of 
local renin - angiotensin systems. Renin, ACE, Angio- 
tensinogen, angiotensin I, angiotensin II and angio- 
tensin receptors have all been demonstrated bio- 
chemically in the walls of small and large arteries and 
veins. 19-21 The extra-renal expression of renin-angio- 
tensin system messenger RNAs and their protein 
products has been confirmed biochemically and by 
Northern blot and in situ hybridization tech- 
niques. 1'2z-26 The components have also been localised 
immunohistochemicall)~ and it has been demon- 
strated that renin is located in both the endothelium 
and the smooth muscle cells, while ACE is located 
mainly in the endotheliumF Angiotensin I has been 
converted to angiotensin II in isolated perfused hearts 
and isolated arteries while there is in vivo evidence for 
the existence of a tissue renin-angiotensin system in 
humans from the results of kinetic analysis of angio- 
tensin I and II differences in arteries and veins in the 
forearm. 25'26'z8'29 It is now believed that angiotensin II,
the end product of this biologic cascade can be 
produced locally in three separate ways: (i) completely 
intracellularly in one cell type i.e. endothelium or 
smooth muscle cells or, (ii) angiotensin I can be 
produced intracellularly and converted to angiotensin 
II by ACE in the cell membrane, or (iii) the compo- 
nents are synthesised in different cell types and 
diffuse into the extracellular fluid where angiotensin II 
is produced. 16 
The precise functions of tissue renin-angiotensin 
system remain to be fully elucidated. It appears that 
the endocrine or kidney based renin-angiotensin 
system is associated with short-term regulation of the 
cardiovascular system while the tissue renin-angio- 
tensin system plays a role in long term regulation of 
cardiovascular homeostasis. B° 
Production of angiotensin II by the endothelium can 
stimulate prostaglandin E2 and I2 production and 
increase nitric oxide release. In the smooth muscle 
cells angiotensin II can directly stimulate contraction 
via specific receptors. Angiotensin II produced by the 
endothelium can also directly stimulate smooth mus- 
cle cells as a mechanism of paracrine activity. Angio- 
tensin II produced from either source can increase the 
release of noradrenaline from the adrenergic 
nervesY -B4 The control of the expression and activity 
of local renin-angiotensin systems has not been fully 
established. Regardless of the mechanism involved, 
increased local production of angiotensin II can result 
in net vasoconstriction and has been postulated as a 
possible mechanism for the pathogenesis of essential 
hypertension. In the spontaneously hypertensive rat 
(SHR) for example, arterial pressure correlates with 
aortic renin production, despite a normal plasma 
renin. B5 In addition, apart from this role in small 
vessels, local angiotensin production may effect the 
contractile state of large conduit arteries. It has been 
shown that ACE inhibition can increase the com- 
pliance in the brachial and carotid arteries in man, 
without a reduction in blood pressure, but this was 
not observed with nitrates or hydralazine. Therefore 
local renin-angiotensin systems could influence the 
conduit and buffering functions of these vessels. 36 
The sequence of events from the binding of angio- 
tensin II to its receptors to subsequent contraction has 
been studied in cultured cells. Binding of angiotensin 
II results in internalisation of its receptor. The internal- 
isation of the receptor results in activation of phospho- 
lipase C. Phospholipase C then activates the phospha- 
tidylinositol cycle, resulting in production of 
inositoltriphosphates and diacylglycerol. These secon- 
dary messengers are then responsible for Ca + + mobili- 
zation, protein kinase C activation, altering cellular 
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pH and further sustained Ca + ÷ release, culminating in 
the protein phosphorylation and contractions -39 Cal- 
cium mobilisation in the adrenal will also increase 
aldosterone secretion. 4° Angiotensin II has also a 
direct inotropic effect on cardiac muscle. 41 The effects 
of angiotensin II on vascular structure in the longer 
term will be discussed below. 
Angiotensin Converting Enzyme 
ACE is the key enzyme involved in the conversion of 
angiotensin I to angiotensin II. ACE has been cloned 
and a detailed analysis shows it to be a membrane 
bound dipeptidyl carboxypeptidase, which catalyses 
the release of histidyl-leucine from the -COOH termi- 
nus of angiotensin I to yield the potent vasoactive 
octapeptide, angiotensin II. It also catalyses the break- 
down of bradykinin. It is a single chain hydrophobic 
protein. The active site is thought to be in the 
extracellular domain and contains tyrosine, arginine, 
glutamine and lysine and acts only in the presence of 
chloride ions. 16'42'43 ACE has been localised to the 
endothelial cells lining all blood vessels. 44 It is also 
present in many parenchymal tissues including the 
testis, adrenal, kidne34 heart, aorta, pulmonary vessels 
etc. 45 ACE activity is not confined to endothelial cells, 
but can be found in smooth muscle cells as has been 
shown in tissue culture and in de-endothelialized 
aorta. 46,47 
It has been suggested that ACE and not renin is the 
rate limiting step in both tissue and endocrine renin- 
angiotensin system. The position of renin as the rate 
limiting step is based on the results of studies of 
plasma renin substrate concentration and enzyme 
substrate kinetics and experiments examining angio- 
tensin II production with different renin concentra- 
tions. These experiments were performed with fixed 
ACE levels and as the serum and tissue ACE concen- 
tration does not vary acutelN renin would appear to 
be the rate limiting step. In certain chronic pathophy- 
siological conditions, however, plasma and tissue ACE 
may increase dramatically. In these situations it has 
been shown that angiotensin II production increases in 
parallel with the increase in ACE, suggesting that ACE 
activity is what determines angiotensin II 
production. 48-s° 
The Renin-Angiotensin System and Vascular 
Disease 
Atherosclerotic vascular disease remains the major 
cause of death in the developed world. It is charac- 
terised by endothelial injury and subsequent smooth 
muscle cell migration across the internal elastic lamina 
and proliferation of these cells. There follows the 
elaboration of a connective tissue matrix and lipid 
deposition forming atherosclerotic plaques, l-53 
All vascular interventions, be they angioplasty, 
embolectom~ stenting, endarterectom~ or bypass 
grafting, ironically result in intimal injury of one form 
or another so perpetuating the proliferative 
events. 54-s9 In femoropopliteal vein bypass grafts 
intimal hyperplasia is the paramount cause of failure 
from as early as 1 month to up to 2 years after 
grafting. 6° Intimal hyperplasia plays an even more 
important role in aortocoronary vein graft failure, 
where concentric luminal narrowing progresses to a 
segmental stenosis of at least 50% in 5-10% of grafts 
after one year. In the 1-5 year period atheromatous 
disease develops in the grafts and intimal hyperplasia 
progresses. 61-63 The results of coronary angioplasty 
are no better, with a 30% restenosis rate at 6 months. 54 
The 5 year patency rate for femoral angioplasty is only 
40% while iliac artery angioplasty fares a little better 
with patency rates at 5 years of 60%. 64 Thus the 
pathogenesis of vein graft failure and restenosis after 
angioplasty appears to be intimately linked to the 
development and progression of intimal hyperplasia. 
There is now a large body of evidence supporting a
role for tissue renin-angiotensin systems in the control 
of vascular smooth muscle cell growth. Several studies 
have shown that there is increased activity of tissue 
renin-angiotensin systems in hypertension, athero- 
sclerosis and following intimal injury. 65-67 The control 
of smooth muscle cell growth by the tissue renin- 
angiotensin system appears to be a complex mecha- 
nism based primarily on the effects of angiotensin II
on smooth muscle cells. 
Angiotensin II has been shown to cause vascular 
myocyte growth in both cultured rat and human aortic 
smooth muscle cells. These growth promoting effects 
appear to be mediated via the angiotensin II receptor 
subtype AT1.68'69 The initial events are mediated 
through the phosphatidyl-inositol cycle as described 
above. 37-39'70 These events also appear to mediate the 
longer term actions of angiotensin II including the 
regulation of gene expression, protein synthesis, DNA 
and RNA synthesis and consequent cell growth and 
alteration of vascular structure. When angiotensin II is 
added to smooth muscle cells in culture there is a 
rapid and sustained increase in RNA and protein 
synthesis with a consequent increase in cell size and 
protein content, but little or no increase in DNA. 71-76 
This effect is achieved by a delicate balance between 
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proto-oncogenes and mitogens and the anti-pro- 
liferative effect of transforming growth factor, ~1 
(TGF-fil). The proto-oncogenes include c-fos, c-myc 
and c-jun. The activation of c-los and c-jun results in 
the formation of a heterodimeric transcription com- 
plex called AP-1 which regulates multiple target 
genes. The cells will thus enter the S-phase in the cell 
cycle and become responsive to growth factors. In 
addition angiotensin II stimulates cell growth via 
secondary mitogens, namely platelet derived growth 
factor-A (PDGF-A) and basic fibroblast growth factor 
(bFGF). Production of these factors has been shown to 
be increased in the presence of angiotensin II and 
inhibition of their production with antisense oligo- 
mers significantly reduced angiotensin II induced 
protein and RNA synthesis in the case of PDGF-A and 
angiotensin induced DNA synthesis with 
bt~GF.71,73, 77-79 
In normal blood vessels these growth promoting 
factors are balanced against the action of TGF-~I. If 
activation of TGF-fix is reduced or inhibited the main 
effect of angiotensin II is to cause hyperplasia of the 
smooth muscle cells, while if TGF-~I is activated, the 
net effect of angiotensin II activity results in hyper- 
trophy and not hyperplasia. 71"8° 
It has been postulated that vascular injury results in 
an imbalance betwen the proliferative and anti- 
proliferative pathways, favouring cellular prolifera- 
tion. This activity is augmented by increased local 
angiotensin II production by the tissue renin-angio- 
tensin system, a further response to endothelial 
denudation. It has been shown that following intimal 
injury there is a doubling of medial smooth muscle 
cell angiotensinogen mRNA expression, and a sig- 
nificant increase in its production in the neo-intima. 67 
ACE, not normally expressed in smooth muscle cells 
can now be easily detected in the neo-intima. 46'47 Thus 
there may be increased local production of angiotensin 
II following intimal injury. These two factors indicate 
that tissue renin-angiotensin system plays a major role 
in the development of intimal hyperplasia after 
vascular injury. 
ACE inhibition and the Prevention of Vascular 
Disease 
The increased understanding of the renin-angiotensin 
system outlined above coupled with the development 
of many inhibitors of ACE inhibitors 81 has led to a 
number of attempts to manipulate the renin-angio- 
tensin system and so modulate the response of blood 
vessels to hypertension, endothelial injur)~ and vein 
grafting. 
Hypertension 
Vascular ACE activity is altered in hypertension. It is 
known that local activity of these systems is increased 
in the spontaneously h pertensive rat (SHR). It is not 
clear from the studies to date whether this is the 
primary cause of the hypertension or if the alterations 
in haemodynamics which occur in the hypertension 
are the stimulus for increased activity. 21 It is clear that 
the angiotensin II produced in these vessels can both 
amplify the vasoconstriction and perpetuate the 
hypertension. Studies using the SHR have shown that 
ACE inhibition can improve endothelial function and 
reduce medial smooth muscle cell hypertrophy and 
hyperplasiaff ,34,82 
Intimal injury 
Intimal injury results in a biological cascade with local 
accumulation of platelets, leucocytes and active 
mediators. This process will initiate smooth muscle 
cell migration, activation and proliferation with the 
consequent development of intimal hyperplasia. 83It 
has been shown that there is increased ACE expres- 
sion following int imal injury. 46'47'67 This will result in 
increased local levels of angiotensin II. The role of 
locally produced angiotensin II in smooth muscle cell 
proliferation following endothelial denudation has 
been elegantly proven in an animal model. Angio- 
tensin II infusion enhanced vascular smooth muscle 
cell proliferation. ACE inhibition failed to inhibit this 
angiotensin II induced hyperplasia. However, in ani- 
mals not receiving an angiotensin II infusion direct 
inhibition of the AT1 angiotensin II receptor with DuP 
753 (Losartan) was as successful as ACE inhibition in 
limiting intimal hyperplasia, s4
The animal model of endothelial denudation using 
a balloon catheter has been extensively used to study 
the effects of endothelial injury such as occur after 
angioplasty, endarterectomy or stenting. 8s-88 Several 
studies have now shown a beneficial effect of ACE 
inhibition in reducing intimal hyperplasia in these 
models. 6'89-92 A linear relationship has been demon- 
strated between tissue ACE and intimal lesion size. 47 
The mechanism involved appears to be the direct 
result of inhibition of angiotensin II production rather 
than the result of haemodynamic effects, such as a 
reduction in blood pressure, as similar studies with 
calcium antagonists failed to show an equivalent 
reduction in intimal hyperplasia. 93ACE also catalyses 
the local breakdown of bradykinin. ACE inhibition 
could therefore result in a local accumulation of 
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bradykinin. Bradykinin can stimulate ndothelial cell 
production of PGI2 and nitric oxide, which are both 
growth inhibitors and could contribute significantly to 
the antiproliferative effect of ACE inhibitors. 94'95 How- 
ever studies with Dup 753, a specific AT1 angiotensin 
II receptor antagonist, show that it is local accumula- 
tion of angiotensin II which is involved in promoting 
smooth muscle cell proliferation. ACE inhibition will 
reduce local levels of angiotensin II and this appears to 
be the mechanism for the antiproliferative action of 
these drugs. 68"84 
The timing of introduction of the ACE inhibitor also 
appears to be important. In animal studies ACE 
inhibition must be adequate at the time of intimal 
proliferation for any effect on intimal hyperplasia. 
Various dose/time regimens have been used and the 
results indicate that adequate ACE inhibition in 
animals requires a high dose or a lon~, ~retreatment if 
intimal hyperplasia is to be reduced. 89"96-98 
The results of animal studies may explain the failure 
of the recent MERCATOR trial to show any benefit 
from treatment with ACE inhibitors in preventing 
restenosis following coronary angioplasty. In this trial 
patients received low dose cilazapril immediately 
after PTCA. The dose was 10% that of the effective 
animal dose and there was no pretreatment. Thus the 
criteria used in animal experiments, i.e. adequate ACE 
inhibition prior to the onset of intimal proliferation, 
were not met. 97"98 It is known that the dose of ACE 
inhibitor/kg required for ACE inhibition is species 
specific. 99 It cannot be discounted that the ACE 
inhibitor mediated reduction in intimal hyperplasia in 
animal models may be also species specific. Further 
clinical studies using a more effective drug concentra- 
tion for a period prior to PTCA are needed to fully test 
this hypothesis. 
Vein grafts 
Vein grafts are the most widely used conduits for 
arterial reconstruction or bypass in the coronary, 
peripheral or renal circulations. Autogenous aphe- 
nous vein, grafted in either the reversed or in situ 
positions in the leg or as a free reversed graft in other 
sites is the most commonly used vein. While it is 
accepted that autogenous vein is the material of choice 
in these situations, disappointment with long term 
patency has stimulated interest in the internal mam- 
mary and gastroepiploic arteries in coronary artery 
100 101 bypass surgery. " In the peripheral circulation, 
however, no arterial substitute is available, and the 
results of infrageniculate reconstruction with pros- 
thetic materials have been disappointing. 1°2 Therefore 
investigators have concentrated on establishing the 
aetiology and natural history of vein graft failure in 
the hope of preserving long term graft patency. The 
pathophysiology of vein graft failure was the subject 
of a recent review in this journal and this review will 
concentrate solely on the role of the renin-angiotensin 
system in vein graft failure. 1°3 
Alterations in the expression and activity of the 
tissue renin-angiotensin system in vein grafts have 
been studied in the rabbit jugular vein/carotid artery 
interposition graft model. These studies have shown 
that rabbit vein grafts undergo fundamental changes 
in their vasomotor responses to angiotensin I and II 
when compared to control veins. The sensitivity and 
maximal response of the grafts is increased, but more 
importantly the character of the response to angio- 
tensin I and II is completely altered and the grafts fail 
to become desensitised tothese agonists unlike control 
veins. ~°4 These changes are most likely due to a 
change in the angiotensin receptor or receptor secon- 
dary messenger system. In normal vessels the receptor 
responsible for angiotensin mediated responses 
appears to be the AT~ receptor subtype. Binding of 
angiotensin II to the AT~ receptor results in sequestra- 
tion of the complex, and the use of the phosphatidyl 
inositol system as described above. Angiotensin II- 
stimulated secondary messenger generation in vas- 
cular smooth muscle cells is complex and involves 
processing of the angiotensin II-receptor complex, 
protein kinase C activation and changes in intra- 
cellular pH. 42 This messenger system must be altered 
in vein grafts in order to obtain the sustained 
contraction observed. The processing of the angio- 
tensin-receptor complex may be quicker in order to 
prevent tachyphylaxis, and this could also help to 
explain the increased sensitivity as rapid receptor 
agonist binding and uncoupling would automatically 
increase receptor number available for activation. This 
may be yet another reflection of the fundamental 
changes in the local responses to angiotensin II which 
as we saw earlier can result in a hyperplastic rather 
than a hypertrophic response in smooth muscle cells. 
The role of other angiotensin II receptor subtypes uch 
as the AT 2 receptor in these processes is as yet 
unclear. 
The activity of a local renin-angiotensin system in 
vein grafts has also been investigated. Vein grafts were 
found to have increased levels of ACE and its 
distribution was not confined to the endothelium as in 
the control veins, but was also shown in the region of 
intimal hyperplasia. This local ACE was functional 
and capable of converting the weak vasoconstrictor 
angiotensin I to angiotensin II and could be inhibited 
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in vitro by the specific ACE inhibitor, captopril. 1°5 
These results mirror the results of studies following 
endothelial injury in arteries and indicate that this 
increased ACE may have a similar role in the control 
of the development of intimal hyperplasia, universally 
seen in vein grafts. 
Several studies have explored the therapeutic appli- 
cations of ACE inhibitors in preventing intimal hyper- 
plasia after vein bypass grafting. Treatment with 
captopril from 7 days prior to grafting reduced intimal 
hyperplasia in rabbit vein grafts by up to 40% at 28 
days. The dose used was biologically equivalent o 
20% that typically used in human and did not cause 
significant hypotension9 6 Similar studies in the same 
model using perindopril produced an equivalent 
reduction in intimal hyperplasia nd preservation of 
nitric oxide production, although these results were 
produced in the presence of reduced blood pressure. 
(de Souza AC, Watt PA, Thurston H, Bell PRF, Spyt TJ. 
The effect of ace inhibition on vein graft morphology 
and function. Presented ESVS VIII, Berlin 1994). In a 
canine model however, cilazapril failed to have any 
effect on the development of intimal hyperplasia. ~°7 
The mechanism involved in the reduction of intimal 
hyperplasia in vein grafts must be similar to that 
postulated for endothelial injury models, in that the 
ACE inhibitor acts by reducing the local level of 
angiotensin II, as losartan, an AT~ receptor antagonist, 
reduced intimal proliferation in human saphenous 
vein in organ culture. 1°8 It is interesting to note the 
low dose of captopril required in the rabbit model. 
This may be an indication of changes in the character 
of ACE in the intimal hyperplasia of these grafts or 
perhaps another pointer to species specificity. The 
results with perindopril show similar reductions in 
intimal hyperplasia nd as this drug has no SH-group 
it seems that the free radical scavenging activity of this 
SH-group in captopril is not responsible for the effect 
on intimal hyperplasia. The vasomotor esponses of 
vein grafts reported in this study are surprising in that 
there is some preservation of endothelial function and 
nitric oxide production even in the untreated grafts. 
This contradicts many previous studies where nitric 
oxide production in vein grafts in response to acet- 
ylcholine could not be demonstrated. 1°9-n2 
In canine vein grafts ACE inhibition with cilazapril 
had no effect on the development of intimal hyper- 
plasia. The reasons for this failure are not clear. ACE 
inhibitors are known to be species specific" in their 
biological activity and there is no information pre- 
sented regarding the completeness or otherwise 6f 
ACE inhibition so like the MERCATOR trial adequate 
ACE inhibition may not have been achieved. 1°7 
The Future 
The discovery that an alteration in the ACE gene is a 
risk factor for coronary artery disease has given new 
impetus to research into the genetic control of local 
renin-angiotensin systems. 11B The polymerase chain 
reaction (PCR) technique has allowed more compre- 
hensive study of renin-angiotensin gene expression in 
many tissues. ~14 The development of effective gene 
transfer techniques has shown that transfected compo- 
nents of the renin-angiotensin system can stimulate 
cell growth and indicate that the control of the 
expression of these genes may hold the key to 
inhibiting intimal hyperplasia after vascular 
injury. ~15'~6 Therapy in the future may be directed at 
the role of the renin angiotensin system in regulating 
the cell cycle. Cell cycle regulatory enzymes are 
activated after vascular injury and their inhibition 
using a single intraluminal dose of an antisense 
oligonucleotide can inhibit intimal hyperplasia. 117 
Conclusions 
Vein bypass grafting and endovascular ngioplasty or 
stenting will remain the cornerstones in the manage- 
ment of vascular disease for the foreseeable future. All 
techniques are beset with intimal hyperplasia. Local 
renin-angiotensin systems clearly exist in blood ves- 
sels. They are involved in the control of vessel tone 
and modulate the remodelling of the vessel in 
response to endothelial injury. ACE inhibition has 
been shown to be of benefit in animal models in 
reducing intimal hyperplasia. There have been no 
properly designed or controlled clinical as yet to 
assess their affects. There is a need for such trials to see 
if the experimental observations translate into clinical 
benefit. In the future gene therapy may hold the key to 
preventing intimal hyperplasia. 
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